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Edited by Varda RotterAbstract Previous reports have shown that metallothionein
(MT) may modulate p53 activity through zinc exchange. How-
ever, little is known on a direct interaction between MT and p53
in cells. The results demonstrate an interaction between MT and
p53 can occur in vitro. The complex between MT and p53 was
observed in breast cancer epithelial cells with both wild and
inactive type of p53. Furthermore, it was shown that wt-p53 was
preferentially associated with Apo-MT. Our data suggest that
co-expression of MT and p53 and their complex formation in
tumor cells may be involved in regulation of apoptosis in these cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Metallothionein (MT) is a family of conserved metal-bind-
ing proteins with a potential role on homeostasis of essential
metals and intracellular storage of metal ions. The aﬃnity of
zinc ions to cysteines in MT provides an eﬃcient mode of
sequestration of zinc, and thus, provides an intracellular
source of zinc for a number of proteins and enzymes such
as, estrogen receptor, transcription factor IIIa and mitochon-
drial aconitase [3,6,9]. MT was found to interact with the
p50 subunits of NF-jB, kinase domain of PKCl and GTPase
Rab3A [1,10,16]. While high expression of MT in certain tu-
mors may block apoptosis and be related to tumor progres-
sion, a central role for p53 is to act as a tumor suppressor
by inducing apoptosis [4]. The tumor suppressor p53 is a tran-
scriptional factor with a key role in maintenance of genome
integrity, regulation of cell cycle and apoptosis. Recent studies
have indicated a strong relationship between p53 and MT since
high expression of MT in tumors is consistently associated
with the presence of mutated p53 and increased tumor grade.
It has been suggested that MT can regulate the DNA binding
activity of p53 through zinc transfer reaction [12]. The zinc
ions are essential for maintenance of the wild-type conforma-
tion and stability of p53 protein and its aﬃnity for speciﬁc
DNA sequence for transcriptional activity of the protein
[13,15]. However, transfer of zinc can also occur in the reverse
direction. The metal-free form of MT (apo-MT) with its 20
sulfhydryl groups can sequester zinc and thereby, reduce theAbbreviations: MT, metallothionein; CD, circular dichroism
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p53 results in a highly aggregation prone conformation [2].
Although MT has been implicated in the control of p53 folding
with zinc exchange, there is little information on direct interac-
tion between MT and p53 proteins. The biological activity of
p53 protein is mainly related to it transcriptional functions,
but it has been suggested that p53 can exert its function via
protein–protein interaction by binding to partner proteins such
as c-Abl, Ref. [1], F-actin, and Bax [5,7,8].
This study was undertaken to examine a potential direct
interaction of p53 and MT. We show that p53 can be associ-
ated with MT both in vivo and in vitro. In vitro, wt-p53 asso-
ciates preferentially with apo-MT.2. Materials and methods
2.1. Cell culture
Human breast cancer epithelial cell line MN-1, containing wt-p53
and the MDD2 cell line, a variant derived fromMCF-7 by transfection
with inactive p53 (pCMVDD-p53; mut-p53), were generously provided
by Dr. C.M. Galmarini, (Laboratoire de Cytologie Analytique,
Faculte´ de Me´decine Rockefeller, France). Both cell lines were origi-
nally made by M. Oren [14] and maintained in complete Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum, 2 mM
L-glutamine, and antibiotics (100 units/ml penicillin and 100 mg/ml
streptomycin).
2.2. Protein preparation
The Zn, Cd-MT was prepared from rabbit livers as described [18].
The glutathione S-transferase (GST)-tagged wt-p53 protein was
isolated from a strain of E. coli that contained the coding sequence
of wild type human p53 (purchased from Protein One, Technology
Dive, College Park, MD 20742).
Apo-MT was prepared by gel-ﬁltration chromatography (Sephadex
G-50) at pH 2, as described by Vasak [19]. Metal-free protein was pre-
pared one day before the experiments and was maintained at pH 2. To
avoid metal contamination, deionized water and metal-free pipette tips
were used throughout. Zinc and cadmium contained in MT was ana-
lyzed by ﬂame atomic absorption spectroscopy. Protein concentrations
of MT and fractions from Sephadex G-50 gel-ﬁltration column were
determined by spectrophotometry (e220 = 48200 M
1 cm1 [19].
2.3. Circular dichroism (CD) spectroscopy
CD spectra were recorded using a J-810 spectropolarimeter (Jasco)
in 10 mM sodium phosphate or 20 mM Tris–HCl (pH 7.4) at 20 C
in 0.1 cm quartz cuvette for far-UV CD spectroscopy. Concentration
of protein was 100 lg/ml. CD spectra were recoded in a spectral range
of 190–260 nm at 25 C. Molecular elipsicity (H) was expressed as
deg cm2 dmol1.
2.4. Co-immunoprecipitation and Western blot analysis
MN1 cells and MDD2 cells were treated with 100 lM of ZnSO4 for
14 h, lysed in lysis buﬀer and centrifuged for 15 min at 12000·g. The
protein concentration was determined using a detergent-compatibleblished by Elsevier B.V. All rights reserved.
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uga, Ontario). The 100 ll of cell extract (5 mg/ml) was immunoprecip-
itated with 10 ll of monoclonal anti-MT (Dako Cytomation Inc.,
Mississauga, Canada) or polyclonal anti-p53 antibodies (clone FL-
393, Santa Cruz, CA). Then, protein A/G-sepharose beads were added
to the immunoprecipitates and mix overnight at 4 C. The beads were
washed 4–5 times with lysis buﬀer, boiled in SDS sample buﬀer, frac-
tionated by SDS–PAGE, and blotted with the indicated primary anti-
bodies.
For Western blot analysis, the whole cell extracts were normalized
for protein and 60 lg of each cell lysate was separated by 12% SDS–
PAGE and blotted with anti-p21 (Santa Cruz, CA) and anti-MT anti-
bodies, followed by HRP-conjugated secondary antibodies. Loading of
equal amount of protein was conﬁrmed by blotting with anti-GAPDH
antibody (HyTest Ltd., Turku, Finland). The bands were visualized by
enhanced chemiluminescence, using ECL reagent and ECL Hyperﬁlm
(Amersham, Que., Canada). All experiments were conducted at least
three times.
2.5. GST-pull-down assay
The 100 lg of GST-tagged p53 protein was attached to glutathione-
Sepharose beads and incubated with puriﬁed rabbit liver MT1 in bind-
ing buﬀer (ProFound pull-down GST protein–protein interaction kit,
Pierce Biotech, Rockfold, IL). The proteins were then separated on
12% gel by SDS–PAGE, followed by Western blot analysis using
anti-p53 or anti-MT antibodies.3. Results
3.1. P53 can interact with MT
In epithelial breast cancer MN1 cells derived from MCF-7
cells with wt-p53, the basal levels of MT and p21 (the down-
stream target of p53) were low (Fig. 1A). Treatment of MN1
cells with zinc (100 lM) resulted in increase in p21 proteinIP
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Fig. 1. (A) Induction of MT and p21, a downstream target gene of p53, by
treated with 100 lM of ZnSO4 for 14 h, were examined for MT and p53 inter
and MDD2 cells treated with or without 100 lM of ZnSO4 for 14 h. The
antibody (B) or with polyclonal p53 antibody (C). The immunoprecipitateslevel, suggesting the cellular accumulation of functional p53.
The elevated p21 expression is mainly associated with stabiliza-
tion and accumulation of functionally active p53. In addition,
as expected there was an increase in MT levels after zinc expo-
sure (Fig. 1A). Unlike MN1, the basal level of MT was high in
epithelial breast cancer MDD2 cells with a inactive form of
p53. Treatment of MDD2 cells with zinc did not signiﬁcantly
change the level of either MT or p21, suggesting a relationship
between expression of p53 and MT in these cells derived from
MCF-7 cells. In order to determine if p53 interacted with MT,
we examined the p53-MT complex formation in MN1 and
MDD2 cells with and without treatment with zinc (Fig. 1B
and C). Using monoclonal anti-MT antibody, p53 protein
was co-precipitated with MT from the protein lysates of both
MN1 cells and MDD2 cells (Fig. 1B). Furthermore, using
polyclonal anti-p53 antibody we also observed co-precipitation
of MT protein in both MN1 and MDD2 cells (Fig. 1C). These
results indicate that p53 and MT can form a complex in epithe-
lial breast cancer cells, irrespective of their p53 status.
3.2. The structural characterization of MT-p53 interaction
Various fractions of rabbit liver MT with diﬀerent metal
content were collected from gelﬁltration chromatography.
The UV/CD spectra of apo-MT and metal containing MT con-
ﬁrmed their structural properties. The fraction with spectrum
displayed a minimum at 200 nm contained mainly apo-MT
(Fig. 2A).
To determine the nature of the p53-MT interaction, we
employed a GST-pull-down assay to analyze the in vitro
GSH-wt-p53 interaction with puriﬁed rabbit liver Cd, Zn-
MT1 and apo-MT1 as described in Fig. 2B. Unbound proteins with p53 MT
control
ZnSO
4 100 M
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ZnSO
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MN1 MDD2
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zinc. Immunoblots of whole-cell extracts, from MN1 and MDD2 cells
action. Co-immunoprecipitation of p53 and MT was examined in MN1
cell extracts were immunoprecipitated (IP) with monoclonal anti-MT
were probed with antibodies to MT or p53.
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Fig. 2. (A) CD proﬁle of Cd, Zn-MT and apo-MT after gel ﬁltration at pH 7.4. (B) p53 binds to apo-MT, but not to Cd, Zn-MT. GST-pull-down
analysis. Aliquots of puriﬁed rabbit liver Cd, Zn-MT1 and apo-MT1, prepared by gel-ﬁltration chromatography were incubated with GST-wt-p53
bound to glutathione-Sepharose. Protein complexes were analyzed by SDS–PAGE. Input was the positive control with p53 alone.
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ized by enhanced chemiluminescence. We found that only apo-
MT was able to bind to immobilized GST-wt-p53. In this
in vitro assay, the interaction of puriﬁed Cd, Zn-MT with
wt-p53 was not detected. Overall, these data indicate that
p53 can bind directly with apo-MT and not with MT.4. Discussion
Although, it is reported that MT can modulate biological
activity of p53 via zinc exchange, there is no direct evidence
that zinc exchange occur through direct interaction between
MT and p53. In order to investigate the possibility of direct
interactions of MT with p53, we performed immunoprecipita-
tion using antibodies to p53 or MT on cell lysates of epithelial
breast cancer cells with diﬀerent p53 status; MN1 cells with wt-
p53 and MDD2 cells with inactive p53. Both these cell lines
were derived from human breast cancer epithelial MCF-7 cells
[14]. Exposure of MN1 cells to zinc resulted in induction of
p53-dependent transcription of p21 and increase in expression
of MT. In these cells, an immune complex between MT and
p53 was observed when p53 was precipitated with anti-MT
antibody and vice versa. Thus both antibodies to p53 and
MT were able to bring down the MT-p53 complex. It is inter-
esting that the complex formation between MT and inactive
p53 was also observed in MDD2 cells with high basal level
of MT. Together these data suggest that MT-p53 complex ex-
ists in the cells.
The metal-free form of MT (apo-MT) is usually only present
in the cell, when it is transiently generated during protein syn-
thesis. It has been shown that apo-MT can regulate the folding
of zinc metalloproteins including the p53 by competing for zinc
[3,11,12,17,21]. It has also been shown, that apo-MT can dis-
rupt the DNA binding activity of TFIIA, Zn-Sp1, and p53
through zinc chelation [12,20,21]. However, a recent report
showed the presence of apo-MT in certain tumor cells and di-
rect biomolecular reactions between apo-MT and the Zn-ﬁnger
sites of TFIIIa [9]. These data are consistent with our resultsbased on of the GST-pull-down assay, which demonstrate that
only apo-MT1, and not MT1, forms a complex with p53. The
complex might be formed by interaction between sulfhydryl
groups of apo-MT and zinc ion of p53 since there was no inter-
action between MT and p53. Our observations suggest that
MT in its apo-form interacts with p53 in the cell and that this
may prevent binding of p53 to DNA and at the same time may
prevent degradation of apo-MT. Thus p53 may not be able to
act as a transcriptional factor, and modulate gene transcrip-
tion and apoptosis. These results also suggest that apo-MT/
MT couple may be involved as a control mechanism to regu-
late p53 activity.References
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